132678Evaluation of the technical & commercial viability of developing an accelerated MERS vaccineClosedFeasibility StudiesInnovate UKAnglo Biopharma Ltd, a UK based british biotech startup, will assess both the commercial and technical potential of a Middle Eastern Respiratory Syndrome (MERS) vaccine. An evaluation of the commercial viability of a novel MERS vaccine towards MERS will be performed. MERS is a disease described by the director of the World Health Organisation (WHO) as a "a threat to the entire world". Anglo Biopharma in colllaboration with the University of Reading will assess the potential of University's baculovirus platform's potential to generate novel vaccine antigen candidates.